Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Thera on twitter with the KEY...

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Oct 02, 2022 3:57pm

159 Views

Post# 35000412

RE:RE:Thera on twitter with the KEY...

I guess you could say this is based on preclinical and Ph1a but with 1b running if they aren't sitting on something that is either a solid, decent responder number or looks odds on to convert into that in the near future then I don't know what......

Given he hasn't shut up. It's time to put up Paul!

longterm56 wrote: Interesting. At first I thought this quote was an "overstatement" by an enthisiastic CEO in front of the public, but if that was the case they would not have continued to publicize it, would they?

-LT

TH1902 wrote: https://twitter.com/Theratech_/status/1575188642175369216?s=20&t=QS8afHeKpFBSgstkF5qaLw